Question · asked by 1 review
GM-CSF vs placebo: Adverse events
- Population
- induction of remission in Crohn's disease
- Intervention
- GM-CSF
- Comparison
- placebo
- Outcome
- Adverse events
GM‐CSF showed no clear difference in adverse events compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
GM‐CSF vs placebo Adverse events · patients with induction of remission in Crohn's disease GM‐CSF showed no clear difference in adverse events compared with placebo (moderate certainty). Sargramostim (GM‐CSF) for induction of remission in Crohn's disease (2011) · Cochrane Headline outcomes only | RR 1.06 [0.99, 1.15] | 2 studies · 251 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Sargramostim (GM‐CSF) for induction of remission in Crohn's disease 2011 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- GM-CSF vs placebo or no treatment · Adults with cancer receiving treatment · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.